ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Acuitive Technologies, Inc. Appoints Dr. Wayne Berberian as Chief Medical Officer

Acuitive Technologies

ALLENDALE, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Acuitive Technologies (Acuitive), a leading orthopedic medical device company focused on complex soft tissue repair and regeneration, announces the appointment of Wayne Berberian, M.D. as Chief Medical Officer. He will provide the clinical direction for the development of regenerative orthopedic products from the company’s portfolio of innovative biomaterials.

With over 30 years of experience in senior clinical, educational, and medical executive roles for leading institutions, such as Rutgers Univ. Hospital, Rutgers Univ., New Jersey Medical School, and Hackensack Univ. Medical Center, he has a proven record of making impactful medical decisions. As a full Professor at the Hackensack Meridian School of Medicine, he uses cutting-edge orthopedic technologies to drive innovation and deliver outstanding patient care.

In addition to his prolific professional accomplishments and numerous medical accolades, Dr. Berberian has authored more than 100 peer-reviewed publications and abstracts, books, monographs, chapters, grants, and reports, and has presented over 150 lectures on “state of the art” topics. His experience and expertise will help lead Acuitive to the forefront of regenerative orthopedics that will touch millions of lives.

"I am thrilled to join Acuitive Technologies at such a transformative time," said Wayne Berberian. "I'm impressed by their unique ability to deliver patient-centric tissue regenerative solutions and mitigate the complications of current biodegradable materials. I look forward to joining their clinical decision team and making personalized treatment recommendations possible for multiple degenerative diseases for the first time. This technology has a significant transformational impact on orthopedic healthcare – repairing and regenerating musculoskeletal diseases, maximizing patient outcomes, and reducing the inefficiencies that arise from ineffective devices that can lead to secondary complications and additional surgery."

"We’re delighted to welcome Dr. Berberian to the Acuitive team at a pivotal time for the company" said Mike McCarthy, CEO of Acuitive. "Our capabilities along with multiple healthcare partners are enabling us to build pioneering products that solve clinical problems and enhance patient care and outcomes. Dr. Berberian’s extensive experience as a clinician and educator along with his deep understanding of healthcare innovations makes him the perfect fit to help drive the growth of our product portfolio."

About Acuitive

Acuitive is a biotechnology company developing innovative regenerative biomaterials for orthopedic devices that participate in the natural healing process of musculoskeletal tissues. Together with its surgeon customers, Acuitive is driven to improve patient outcomes by delivering best in class tissue regenerative solutions. More information is available at www.acuitivetech.com.

Media Contact

Thomas McCarthy
Acuitive Technologies, Inc.
tmccarthy@acuitivetech.com
201.661.2680

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/839098ff-91ba-4613-b6c2-ec3ab6396770


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.